| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 89 | 2023 | 8788 | 4.500 |
Why?
|
| Glioblastoma | 58 | 2023 | 3431 | 4.000 |
Why?
|
| Neurosurgical Procedures | 32 | 2023 | 1994 | 3.210 |
Why?
|
| Glioma | 26 | 2022 | 3378 | 2.470 |
Why?
|
| Intracranial Aneurysm | 22 | 2016 | 1180 | 1.760 |
Why?
|
| Craniotomy | 11 | 2021 | 728 | 1.320 |
Why?
|
| Neurosurgery | 8 | 2023 | 643 | 1.240 |
Why?
|
| Subarachnoid Hemorrhage | 15 | 2017 | 1018 | 1.150 |
Why?
|
| Supratentorial Neoplasms | 3 | 2015 | 160 | 1.130 |
Why?
|
| Neuroma, Acoustic | 3 | 2018 | 449 | 0.970 |
Why?
|
| Exosomes | 8 | 2017 | 412 | 0.930 |
Why?
|
| Dacarbazine | 7 | 2017 | 567 | 0.860 |
Why?
|
| Intracranial Arteriovenous Malformations | 6 | 2016 | 356 | 0.820 |
Why?
|
| Cranial Nerve Neoplasms | 3 | 2016 | 129 | 0.800 |
Why?
|
| Levulinic Acids | 1 | 2019 | 18 | 0.720 |
Why?
|
| Radiosurgery | 15 | 2018 | 1305 | 0.710 |
Why?
|
| Cerebral Infarction | 6 | 2014 | 1004 | 0.710 |
Why?
|
| Brain Edema | 6 | 2016 | 617 | 0.690 |
Why?
|
| Radiation Injuries | 4 | 2020 | 1161 | 0.690 |
Why?
|
| Intracranial Hemorrhages | 2 | 2015 | 846 | 0.690 |
Why?
|
| Cerebrospinal Fluid | 4 | 2022 | 536 | 0.690 |
Why?
|
| Protoporphyrins | 1 | 2019 | 163 | 0.690 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2020 | 230 | 0.660 |
Why?
|
| Spinal Fractures | 2 | 2015 | 697 | 0.650 |
Why?
|
| Genetic Vectors | 9 | 2018 | 3421 | 0.640 |
Why?
|
| Otologic Surgical Procedures | 2 | 2018 | 141 | 0.620 |
Why?
|
| Patient Readmission | 4 | 2018 | 3106 | 0.610 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2012 | 545 | 0.610 |
Why?
|
| Parkinson Disease | 5 | 2023 | 2775 | 0.600 |
Why?
|
| Humans | 245 | 2023 | 739219 | 0.590 |
Why?
|
| Hematoma, Subdural, Acute | 1 | 2016 | 18 | 0.590 |
Why?
|
| Astrocytoma | 7 | 2018 | 789 | 0.580 |
Why?
|
| Meningioma | 6 | 2021 | 1202 | 0.570 |
Why?
|
| Immunotherapy, Adoptive | 5 | 2021 | 1239 | 0.570 |
Why?
|
| Aneurysm, Ruptured | 7 | 2008 | 445 | 0.540 |
Why?
|
| Stereotaxic Techniques | 5 | 2021 | 535 | 0.530 |
Why?
|
| Telomerase | 1 | 2020 | 729 | 0.530 |
Why?
|
| Photosensitizing Agents | 1 | 2019 | 602 | 0.520 |
Why?
|
| Vascular Surgical Procedures | 7 | 2007 | 1471 | 0.500 |
Why?
|
| Antigen-Presenting Cells | 1 | 2018 | 969 | 0.500 |
Why?
|
| Postoperative Complications | 24 | 2018 | 15191 | 0.490 |
Why?
|
| Body Fluids | 1 | 2016 | 318 | 0.490 |
Why?
|
| Cell Line, Tumor | 23 | 2020 | 16624 | 0.470 |
Why?
|
| Gene Amplification | 2 | 2017 | 1061 | 0.460 |
Why?
|
| Peripheral Nerves | 1 | 2017 | 481 | 0.460 |
Why?
|
| Xenograft Model Antitumor Assays | 7 | 2020 | 3557 | 0.460 |
Why?
|
| Decompression, Surgical | 5 | 2015 | 592 | 0.450 |
Why?
|
| Lateral Ventricles | 3 | 2020 | 141 | 0.450 |
Why?
|
| Neoplastic Cells, Circulating | 4 | 2023 | 908 | 0.450 |
Why?
|
| Tumor Burden | 9 | 2020 | 1904 | 0.430 |
Why?
|
| Transduction, Genetic | 2 | 2018 | 917 | 0.430 |
Why?
|
| Specialization | 1 | 2017 | 776 | 0.420 |
Why?
|
| Oligodendroglioma | 4 | 2017 | 279 | 0.420 |
Why?
|
| Hydrogels | 1 | 2017 | 720 | 0.410 |
Why?
|
| Diffuse Cerebral Sclerosis of Schilder | 1 | 2011 | 17 | 0.410 |
Why?
|
| Male | 125 | 2021 | 348967 | 0.400 |
Why?
|
| Fluorescent Dyes | 1 | 2019 | 1920 | 0.400 |
Why?
|
| Middle Aged | 99 | 2021 | 212833 | 0.400 |
Why?
|
| Cell-Derived Microparticles | 1 | 2013 | 168 | 0.390 |
Why?
|
| Neostriatum | 2 | 2023 | 249 | 0.390 |
Why?
|
| Decision Making | 2 | 2015 | 3854 | 0.390 |
Why?
|
| Infarction, Middle Cerebral Artery | 2 | 2005 | 474 | 0.390 |
Why?
|
| Neoplasms | 9 | 2023 | 21499 | 0.390 |
Why?
|
| Extracellular Space | 1 | 2013 | 594 | 0.390 |
Why?
|
| Hemispherectomy | 1 | 2011 | 44 | 0.390 |
Why?
|
| Health Care Costs | 2 | 2015 | 3226 | 0.380 |
Why?
|
| Neurilemmoma | 1 | 2016 | 546 | 0.380 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2016 | 744 | 0.370 |
Why?
|
| T-Lymphocytes | 7 | 2019 | 10140 | 0.370 |
Why?
|
| Aged | 81 | 2021 | 162667 | 0.360 |
Why?
|
| Medically Uninsured | 1 | 2016 | 851 | 0.360 |
Why?
|
| Glasgow Outcome Scale | 3 | 2006 | 109 | 0.350 |
Why?
|
| Adult | 82 | 2021 | 213375 | 0.350 |
Why?
|
| Treatment Outcome | 43 | 2023 | 62691 | 0.340 |
Why?
|
| Female | 108 | 2021 | 378808 | 0.340 |
Why?
|
| Spinal Cord Injuries | 1 | 2017 | 932 | 0.340 |
Why?
|
| California | 5 | 2016 | 1400 | 0.340 |
Why?
|
| Vasospasm, Intracranial | 7 | 2007 | 206 | 0.330 |
Why?
|
| Spinal Cord | 1 | 2017 | 1818 | 0.330 |
Why?
|
| Embolization, Therapeutic | 9 | 2012 | 1376 | 0.330 |
Why?
|
| Gene Transfer Techniques | 3 | 2010 | 1227 | 0.330 |
Why?
|
| Fibronectins | 1 | 2012 | 723 | 0.330 |
Why?
|
| Mutation | 14 | 2023 | 29659 | 0.330 |
Why?
|
| Oncolytic Viruses | 1 | 2012 | 321 | 0.330 |
Why?
|
| Pituitary Neoplasms | 4 | 2018 | 1334 | 0.320 |
Why?
|
| Endostatins | 1 | 2008 | 174 | 0.310 |
Why?
|
| Gene Expression | 3 | 2018 | 7789 | 0.310 |
Why?
|
| Psychomotor Performance | 1 | 2016 | 1898 | 0.310 |
Why?
|
| Microsurgery | 3 | 2009 | 793 | 0.300 |
Why?
|
| Brain | 15 | 2023 | 26293 | 0.300 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2008 | 194 | 0.300 |
Why?
|
| Aged, 80 and over | 36 | 2021 | 57639 | 0.290 |
Why?
|
| Oncolytic Virotherapy | 1 | 2012 | 489 | 0.290 |
Why?
|
| Depressive Disorder | 2 | 2016 | 3743 | 0.290 |
Why?
|
| DNA Modification Methylases | 2 | 2020 | 205 | 0.290 |
Why?
|
| Orthopedics | 1 | 2016 | 900 | 0.290 |
Why?
|
| Luciferases, Firefly | 1 | 2006 | 46 | 0.270 |
Why?
|
| Adenoma | 4 | 2018 | 2163 | 0.270 |
Why?
|
| Hydrocephalus | 2 | 2023 | 744 | 0.270 |
Why?
|
| Retroviridae | 3 | 2018 | 914 | 0.270 |
Why?
|
| Status Epilepticus | 1 | 2011 | 435 | 0.270 |
Why?
|
| Magnetic Resonance Imaging | 17 | 2020 | 35274 | 0.270 |
Why?
|
| Carotid Artery, Internal | 4 | 2017 | 441 | 0.270 |
Why?
|
| DNA Repair Enzymes | 2 | 2020 | 347 | 0.270 |
Why?
|
| Dependovirus | 1 | 2010 | 710 | 0.260 |
Why?
|
| Anxiety Disorders | 1 | 2016 | 2674 | 0.260 |
Why?
|
| Meningeal Neoplasms | 5 | 2021 | 1234 | 0.260 |
Why?
|
| Histiocytosis, Langerhans-Cell | 2 | 2018 | 172 | 0.260 |
Why?
|
| SEER Program | 7 | 2018 | 1506 | 0.250 |
Why?
|
| Education, Medical, Graduate | 2 | 2023 | 2275 | 0.240 |
Why?
|
| Kaplan-Meier Estimate | 12 | 2021 | 6517 | 0.240 |
Why?
|
| Animals | 38 | 2023 | 168358 | 0.240 |
Why?
|
| Antineoplastic Agents, Alkylating | 4 | 2017 | 627 | 0.240 |
Why?
|
| Prognosis | 23 | 2021 | 28901 | 0.240 |
Why?
|
| Neoplastic Stem Cells | 4 | 2020 | 1375 | 0.240 |
Why?
|
| MicroRNAs | 9 | 2020 | 3710 | 0.230 |
Why?
|
| General Surgery | 1 | 2015 | 1630 | 0.230 |
Why?
|
| Mice | 27 | 2023 | 80995 | 0.230 |
Why?
|
| Clinical Trials as Topic | 3 | 2012 | 7897 | 0.230 |
Why?
|
| Review Literature as Topic | 1 | 2005 | 328 | 0.230 |
Why?
|
| Retrospective Studies | 46 | 2021 | 76632 | 0.230 |
Why?
|
| Otolaryngology | 2 | 2020 | 644 | 0.230 |
Why?
|
| Vein of Galen Malformations | 1 | 2023 | 53 | 0.220 |
Why?
|
| Transport Vesicles | 2 | 2014 | 83 | 0.220 |
Why?
|
| Gene Expression Regulation, Neoplastic | 12 | 2020 | 8395 | 0.220 |
Why?
|
| Aminolevulinic Acid | 2 | 2022 | 143 | 0.220 |
Why?
|
| Neoplasm, Residual | 2 | 2018 | 970 | 0.220 |
Why?
|
| Balloon Occlusion | 2 | 2001 | 126 | 0.220 |
Why?
|
| Diuretics, Osmotic | 1 | 2002 | 37 | 0.210 |
Why?
|
| Arachnoid Cysts | 1 | 2023 | 59 | 0.210 |
Why?
|
| Stem Cell Transplantation | 3 | 2020 | 1628 | 0.210 |
Why?
|
| Cerebral Angiography | 8 | 2016 | 1282 | 0.210 |
Why?
|
| Follow-Up Studies | 22 | 2020 | 38941 | 0.210 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 2023 | 375 | 0.210 |
Why?
|
| Brain Damage, Chronic | 2 | 2000 | 264 | 0.210 |
Why?
|
| RNA, Neoplasm | 2 | 2017 | 760 | 0.210 |
Why?
|
| Endoscopy | 4 | 2020 | 1762 | 0.210 |
Why?
|
| Inpatients | 3 | 2019 | 2478 | 0.210 |
Why?
|
| Hospital Mortality | 8 | 2010 | 5305 | 0.200 |
Why?
|
| RNA | 5 | 2023 | 2727 | 0.200 |
Why?
|
| Research | 2 | 2016 | 2001 | 0.200 |
Why?
|
| Psychotic Disorders | 1 | 2016 | 3028 | 0.200 |
Why?
|
| Flucytosine | 2 | 2018 | 33 | 0.200 |
Why?
|
| Brain Diseases | 2 | 2018 | 1551 | 0.200 |
Why?
|
| Cerebral Revascularization | 3 | 2003 | 235 | 0.200 |
Why?
|
| Skull Base Neoplasms | 2 | 2017 | 277 | 0.200 |
Why?
|
| Survival Rate | 15 | 2020 | 12760 | 0.200 |
Why?
|
| Cerebrovascular Disorders | 2 | 2007 | 1498 | 0.200 |
Why?
|
| Electrophoresis, Microchip | 2 | 2019 | 14 | 0.200 |
Why?
|
| Cytosine Deaminase | 2 | 2018 | 69 | 0.200 |
Why?
|
| Angioplasty | 1 | 2004 | 363 | 0.190 |
Why?
|
| Cohort Studies | 18 | 2020 | 40385 | 0.190 |
Why?
|
| Electrochemical Techniques | 1 | 2021 | 98 | 0.190 |
Why?
|
| Induced Pluripotent Stem Cells | 3 | 2023 | 1705 | 0.190 |
Why?
|
| Aerosols | 2 | 2020 | 619 | 0.190 |
Why?
|
| Intracranial Pressure | 2 | 2002 | 327 | 0.190 |
Why?
|
| Meta-Analysis as Topic | 1 | 2005 | 1339 | 0.190 |
Why?
|
| Surgical Instruments | 4 | 2014 | 395 | 0.190 |
Why?
|
| Endovascular Procedures | 1 | 2014 | 1947 | 0.190 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2018 | 1369 | 0.190 |
Why?
|
| Prostatic Neoplasms | 15 | 1998 | 10995 | 0.190 |
Why?
|
| Encephalocele | 2 | 2002 | 138 | 0.190 |
Why?
|
| Gene Order | 2 | 2018 | 175 | 0.190 |
Why?
|
| Workload | 2 | 2003 | 843 | 0.180 |
Why?
|
| Choroid Plexus | 1 | 2023 | 230 | 0.180 |
Why?
|
| Disease Models, Animal | 8 | 2020 | 18002 | 0.180 |
Why?
|
| Rehabilitation, Vocational | 1 | 2000 | 82 | 0.180 |
Why?
|
| Mice, Nude | 7 | 2020 | 3688 | 0.180 |
Why?
|
| Surgery, Computer-Assisted | 2 | 2019 | 1005 | 0.180 |
Why?
|
| Biopsy, Needle | 2 | 2021 | 1637 | 0.180 |
Why?
|
| Dopamine | 4 | 2023 | 1591 | 0.180 |
Why?
|
| Sensitivity and Specificity | 5 | 2020 | 14721 | 0.180 |
Why?
|
| Validation Studies as Topic | 1 | 2020 | 159 | 0.180 |
Why?
|
| Peptide Fragments | 1 | 2012 | 5073 | 0.180 |
Why?
|
| Trigeminal Neuralgia | 2 | 2016 | 113 | 0.180 |
Why?
|
| Evoked Potentials, Somatosensory | 1 | 2021 | 247 | 0.180 |
Why?
|
| Nose Diseases | 1 | 2020 | 82 | 0.180 |
Why?
|
| Parkinson Disease, Secondary | 1 | 2020 | 126 | 0.170 |
Why?
|
| Radiation Tolerance | 2 | 2020 | 485 | 0.170 |
Why?
|
| Bipolar Disorder | 1 | 2016 | 5024 | 0.170 |
Why?
|
| Spinal Diseases | 2 | 2016 | 540 | 0.170 |
Why?
|
| Teaching Materials | 1 | 2019 | 86 | 0.170 |
Why?
|
| Longitudinal Studies | 8 | 2021 | 13880 | 0.170 |
Why?
|
| Karnofsky Performance Status | 5 | 2017 | 173 | 0.170 |
Why?
|
| Isocitrate Dehydrogenase | 4 | 2020 | 869 | 0.170 |
Why?
|
| Survival Analysis | 10 | 2020 | 10248 | 0.170 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2018 | 9124 | 0.170 |
Why?
|
| Optical Phenomena | 1 | 2019 | 107 | 0.160 |
Why?
|
| Necrosis | 2 | 2020 | 1641 | 0.160 |
Why?
|
| Neurocytoma | 1 | 2018 | 30 | 0.160 |
Why?
|
| Periodicals as Topic | 3 | 2016 | 1428 | 0.160 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 3143 | 0.160 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2019 | 526 | 0.160 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 3248 | 0.160 |
Why?
|
| Schizophrenia | 1 | 2016 | 6867 | 0.160 |
Why?
|
| Proportional Hazards Models | 9 | 2018 | 12328 | 0.150 |
Why?
|
| Activities of Daily Living | 4 | 2005 | 2410 | 0.150 |
Why?
|
| Age Factors | 14 | 2018 | 18347 | 0.150 |
Why?
|
| Nasal Cavity | 1 | 2020 | 305 | 0.150 |
Why?
|
| Patient Discharge | 3 | 2021 | 3286 | 0.150 |
Why?
|
| Mydriasis | 1 | 2017 | 15 | 0.150 |
Why?
|
| Cell Survival | 4 | 2020 | 5873 | 0.150 |
Why?
|
| Nimodipine | 1 | 2017 | 54 | 0.150 |
Why?
|
| Image Processing, Computer-Assisted | 5 | 2018 | 8919 | 0.150 |
Why?
|
| Feasibility Studies | 5 | 2021 | 5050 | 0.150 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2018 | 285 | 0.150 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 253 | 0.150 |
Why?
|
| Drug Compounding | 1 | 2018 | 242 | 0.150 |
Why?
|
| Antibodies, Bispecific | 1 | 2019 | 164 | 0.150 |
Why?
|
| Spinal Fusion | 3 | 2015 | 1236 | 0.150 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2020 | 2843 | 0.150 |
Why?
|
| Mental Disorders | 1 | 2016 | 6570 | 0.140 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 1 | 2020 | 311 | 0.140 |
Why?
|
| Neoplasm Metastasis | 4 | 2018 | 4832 | 0.140 |
Why?
|
| Microarray Analysis | 2 | 2017 | 759 | 0.140 |
Why?
|
| Nose | 1 | 2020 | 499 | 0.140 |
Why?
|
| Young Adult | 16 | 2021 | 56252 | 0.140 |
Why?
|
| Craniocerebral Trauma | 1 | 2001 | 477 | 0.140 |
Why?
|
| Disease Progression | 8 | 2020 | 13237 | 0.140 |
Why?
|
| Transfection | 6 | 2014 | 5884 | 0.140 |
Why?
|
| Gene Expression Profiling | 7 | 2015 | 9393 | 0.140 |
Why?
|
| Drugs, Investigational | 1 | 2018 | 215 | 0.140 |
Why?
|
| Palliative Care | 1 | 2011 | 3461 | 0.140 |
Why?
|
| RNA, Untranslated | 2 | 2017 | 452 | 0.140 |
Why?
|
| Coma | 2 | 2016 | 471 | 0.140 |
Why?
|
| Antineoplastic Agents | 3 | 2017 | 13622 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2014 | 11411 | 0.130 |
Why?
|
| Radiotherapy | 2 | 2020 | 1524 | 0.130 |
Why?
|
| Dominance, Cerebral | 1 | 1997 | 635 | 0.130 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2006 | 2037 | 0.130 |
Why?
|
| Saliva | 1 | 2020 | 805 | 0.130 |
Why?
|
| Brachial Plexus | 1 | 2017 | 165 | 0.130 |
Why?
|
| S100 Proteins | 1 | 2016 | 259 | 0.130 |
Why?
|
| Publication Bias | 1 | 2016 | 159 | 0.130 |
Why?
|
| Polymerase Chain Reaction | 4 | 2020 | 6176 | 0.130 |
Why?
|
| Middle Cerebral Artery | 2 | 2009 | 277 | 0.130 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2016 | 168 | 0.130 |
Why?
|
| tau Proteins | 2 | 2019 | 1845 | 0.130 |
Why?
|
| Adolescent | 24 | 2021 | 85409 | 0.130 |
Why?
|
| Neuroendoscopy | 1 | 2016 | 105 | 0.130 |
Why?
|
| Vascular Diseases | 1 | 2023 | 1152 | 0.130 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 2015 | 90 | 0.130 |
Why?
|
| Combined Modality Therapy | 11 | 2018 | 8605 | 0.130 |
Why?
|
| Thalamus | 1 | 2021 | 1019 | 0.130 |
Why?
|
| Receptor-Like Protein Tyrosine Phosphatases, Class 5 | 1 | 2014 | 17 | 0.130 |
Why?
|
| Facial Pain | 1 | 2016 | 124 | 0.130 |
Why?
|
| Neuronavigation | 1 | 2016 | 167 | 0.130 |
Why?
|
| Mice, SCID | 3 | 2020 | 2714 | 0.130 |
Why?
|
| Nanoparticles | 2 | 2019 | 1896 | 0.120 |
Why?
|
| Glasgow Coma Scale | 5 | 2005 | 568 | 0.120 |
Why?
|
| Glutarates | 1 | 2016 | 235 | 0.120 |
Why?
|
| Hospital Charges | 4 | 2004 | 359 | 0.120 |
Why?
|
| Carotid Stenosis | 2 | 2017 | 851 | 0.120 |
Why?
|
| Immune Evasion | 1 | 2018 | 357 | 0.120 |
Why?
|
| Cranial Irradiation | 2 | 2017 | 402 | 0.120 |
Why?
|
| Retreatment | 1 | 2016 | 603 | 0.120 |
Why?
|
| Antigens, Neoplasm | 2 | 2019 | 1977 | 0.120 |
Why?
|
| Peer Review | 1 | 2016 | 207 | 0.120 |
Why?
|
| Drug Synergism | 1 | 2018 | 1790 | 0.120 |
Why?
|
| Green Fluorescent Proteins | 2 | 2010 | 2093 | 0.120 |
Why?
|
| Flow Cytometry | 3 | 2016 | 5959 | 0.120 |
Why?
|
| Eyelid Diseases | 1 | 2016 | 154 | 0.120 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2016 | 717 | 0.120 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2021 | 1378 | 0.120 |
Why?
|
| Dysarthria | 1 | 2013 | 54 | 0.120 |
Why?
|
| Neoplasm Proteins | 2 | 2021 | 3693 | 0.120 |
Why?
|
| Comprehension | 1 | 2019 | 607 | 0.120 |
Why?
|
| Meningeal Carcinomatosis | 1 | 2014 | 65 | 0.120 |
Why?
|
| Comorbidity | 3 | 2016 | 10362 | 0.120 |
Why?
|
| Reoperation | 4 | 2016 | 4192 | 0.120 |
Why?
|
| Neoplasms, Plasma Cell | 1 | 2013 | 36 | 0.120 |
Why?
|
| Seizures | 2 | 2019 | 2829 | 0.120 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2016 | 2731 | 0.110 |
Why?
|
| Motor Cortex | 1 | 2021 | 984 | 0.110 |
Why?
|
| Preoperative Care | 3 | 2020 | 2237 | 0.110 |
Why?
|
| Hospitals | 3 | 2003 | 3916 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 10 | 2 | 1991 | 287 | 0.110 |
Why?
|
| Monitoring, Intraoperative | 2 | 2019 | 954 | 0.110 |
Why?
|
| Pilot Projects | 5 | 2019 | 8272 | 0.110 |
Why?
|
| Hearing | 1 | 2017 | 478 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 16 | 3 | 1992 | 355 | 0.110 |
Why?
|
| Risk Factors | 21 | 2020 | 71972 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2014 | 9812 | 0.110 |
Why?
|
| Operating Rooms | 2 | 2020 | 804 | 0.110 |
Why?
|
| Peer Review, Research | 1 | 2016 | 327 | 0.110 |
Why?
|
| Natural Language Processing | 1 | 2021 | 1024 | 0.110 |
Why?
|
| Gene Rearrangement | 1 | 2018 | 1179 | 0.110 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2017 | 599 | 0.110 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2021 | 894 | 0.110 |
Why?
|
| Interleukin-13 Receptor alpha2 Subunit | 1 | 2012 | 14 | 0.110 |
Why?
|
| Microelectrodes | 3 | 2019 | 301 | 0.110 |
Why?
|
| Graft Survival | 1 | 2023 | 3724 | 0.110 |
Why?
|
| Multivariate Analysis | 11 | 2017 | 12235 | 0.110 |
Why?
|
| Mice, Inbred NOD | 2 | 2019 | 1866 | 0.110 |
Why?
|
| Signal Transduction | 7 | 2023 | 23355 | 0.110 |
Why?
|
| Cytarabine | 1 | 2014 | 685 | 0.110 |
Why?
|
| Enbucrilate | 1 | 2012 | 31 | 0.110 |
Why?
|
| Disease Management | 3 | 2017 | 2448 | 0.110 |
Why?
|
| Motor Neurons | 1 | 2017 | 843 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 10 | 2020 | 20038 | 0.100 |
Why?
|
| Drug Monitoring | 1 | 2018 | 961 | 0.100 |
Why?
|
| Brain Mapping | 2 | 2019 | 6661 | 0.100 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2020 | 2015 | 0.100 |
Why?
|
| DNA, Viral | 1 | 1999 | 2225 | 0.100 |
Why?
|
| Bibliometrics | 1 | 2016 | 340 | 0.100 |
Why?
|
| Temporal Lobe | 2 | 2018 | 1670 | 0.100 |
Why?
|
| Endarterectomy, Carotid | 1 | 2017 | 543 | 0.100 |
Why?
|
| Intraoperative Complications | 1 | 2019 | 1184 | 0.100 |
Why?
|
| Edema | 1 | 2016 | 791 | 0.100 |
Why?
|
| Cytokines | 3 | 2020 | 7296 | 0.100 |
Why?
|
| Central Nervous System Diseases | 1 | 2016 | 523 | 0.100 |
Why?
|
| Cerebellar Diseases | 1 | 2014 | 226 | 0.100 |
Why?
|
| DNA Mutational Analysis | 1 | 2020 | 4184 | 0.100 |
Why?
|
| Age Distribution | 2 | 2016 | 2903 | 0.100 |
Why?
|
| Internet | 2 | 2019 | 3048 | 0.100 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2014 | 475 | 0.100 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2014 | 282 | 0.100 |
Why?
|
| Risk | 3 | 2016 | 9684 | 0.100 |
Why?
|
| Polyvinyls | 1 | 2012 | 157 | 0.100 |
Why?
|
| Databases as Topic | 2 | 2004 | 473 | 0.100 |
Why?
|
| Dimethyl Sulfoxide | 1 | 2012 | 246 | 0.100 |
Why?
|
| Acetamides | 1 | 2013 | 248 | 0.100 |
Why?
|
| Prospective Studies | 13 | 2021 | 53036 | 0.100 |
Why?
|
| RNA, Messenger | 5 | 2017 | 13006 | 0.100 |
Why?
|
| Genes, ras | 2 | 1991 | 690 | 0.100 |
Why?
|
| Pluripotent Stem Cells | 1 | 2018 | 791 | 0.100 |
Why?
|
| Muscle Weakness | 1 | 2014 | 412 | 0.100 |
Why?
|
| Databases, Factual | 8 | 2021 | 7689 | 0.100 |
Why?
|
| United States | 16 | 2023 | 69568 | 0.100 |
Why?
|
| Length of Stay | 8 | 2019 | 6294 | 0.100 |
Why?
|
| Computer Systems | 1 | 2012 | 484 | 0.100 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 2011 | 85 | 0.100 |
Why?
|
| Promoter Regions, Genetic | 2 | 2020 | 5863 | 0.090 |
Why?
|
| Mentors | 1 | 2016 | 632 | 0.090 |
Why?
|
| Intracranial Hypertension | 2 | 2004 | 185 | 0.090 |
Why?
|
| Receptors, Growth Factor | 2 | 2002 | 334 | 0.090 |
Why?
|
| Immunohistochemistry | 6 | 2014 | 11348 | 0.090 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2014 | 640 | 0.090 |
Why?
|
| Gene Deletion | 1 | 2018 | 2757 | 0.090 |
Why?
|
| Aftercare | 1 | 2016 | 858 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2014 | 578 | 0.090 |
Why?
|
| Microspheres | 1 | 2013 | 778 | 0.090 |
Why?
|
| Internal Fixators | 1 | 2011 | 189 | 0.090 |
Why?
|
| Cerebral Hemorrhage | 3 | 2016 | 2627 | 0.090 |
Why?
|
| Evidence-Based Medicine | 3 | 2016 | 3606 | 0.090 |
Why?
|
| Time Factors | 8 | 2023 | 40040 | 0.090 |
Why?
|
| Postoperative Period | 4 | 2018 | 1835 | 0.090 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2023 | 2985 | 0.090 |
Why?
|
| Microfluidics | 1 | 2015 | 661 | 0.090 |
Why?
|
| Motor Activity | 1 | 2020 | 2718 | 0.090 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2011 | 358 | 0.090 |
Why?
|
| Recovery of Function | 1 | 2020 | 2924 | 0.090 |
Why?
|
| Spine | 1 | 2016 | 1144 | 0.090 |
Why?
|
| Research Design | 2 | 2020 | 5959 | 0.090 |
Why?
|
| Genes, Dominant | 1 | 1992 | 883 | 0.090 |
Why?
|
| American Heart Association | 1 | 2014 | 1050 | 0.090 |
Why?
|
| Heparitin Sulfate | 1 | 2010 | 224 | 0.080 |
Why?
|
| Algorithms | 4 | 2021 | 13828 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 6 | 2020 | 6310 | 0.080 |
Why?
|
| Receptors, Antigen, T-Cell | 3 | 2018 | 2518 | 0.080 |
Why?
|
| Patient Education as Topic | 1 | 2019 | 2275 | 0.080 |
Why?
|
| RNA Transport | 1 | 2008 | 52 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2015 | 4746 | 0.080 |
Why?
|
| Language | 1 | 2018 | 1447 | 0.080 |
Why?
|
| Weights and Measures | 1 | 2008 | 43 | 0.080 |
Why?
|
| Centralized Hospital Services | 2 | 2005 | 18 | 0.080 |
Why?
|
| Serum | 1 | 2009 | 210 | 0.080 |
Why?
|
| Hyperglycemia | 2 | 2009 | 1357 | 0.080 |
Why?
|
| Publishing | 1 | 2016 | 828 | 0.080 |
Why?
|
| Caspase 3 | 1 | 2010 | 758 | 0.080 |
Why?
|
| Virion | 1 | 2010 | 435 | 0.080 |
Why?
|
| RNA, Small Interfering | 2 | 2015 | 3500 | 0.080 |
Why?
|
| Melanoma | 2 | 2018 | 5446 | 0.080 |
Why?
|
| Massachusetts | 2 | 2016 | 8668 | 0.080 |
Why?
|
| DNA Damage | 2 | 2015 | 2416 | 0.080 |
Why?
|
| Deglutition Disorders | 1 | 2013 | 607 | 0.080 |
Why?
|
| Health Care Surveys | 1 | 2015 | 2448 | 0.080 |
Why?
|
| Angiopoietin-1 | 1 | 2008 | 114 | 0.080 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2011 | 435 | 0.080 |
Why?
|
| DNA Repair | 2 | 2020 | 2032 | 0.080 |
Why?
|
| Alzheimer Disease | 1 | 2008 | 7957 | 0.080 |
Why?
|
| Methotrexate | 1 | 2014 | 1710 | 0.080 |
Why?
|
| Socioeconomic Factors | 4 | 2023 | 7726 | 0.080 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2015 | 4549 | 0.070 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2011 | 588 | 0.070 |
Why?
|
| Tumor Microenvironment | 4 | 2022 | 3505 | 0.070 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2008 | 641 | 0.070 |
Why?
|
| Mice, Transgenic | 1 | 2019 | 9738 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 1 | 2015 | 3599 | 0.070 |
Why?
|
| Microfluidic Analytical Techniques | 2 | 2012 | 827 | 0.070 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2012 | 964 | 0.070 |
Why?
|
| Neovascularization, Pathologic | 3 | 2008 | 2639 | 0.070 |
Why?
|
| Viral Envelope Proteins | 1 | 2010 | 635 | 0.070 |
Why?
|
| Health Care Reform | 1 | 2016 | 1258 | 0.070 |
Why?
|
| Registries | 3 | 2016 | 8039 | 0.070 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2014 | 1574 | 0.070 |
Why?
|
| Bibliography of Medicine | 1 | 2005 | 4 | 0.070 |
Why?
|
| Child | 12 | 2019 | 77029 | 0.070 |
Why?
|
| Statistical Distributions | 1 | 2006 | 64 | 0.070 |
Why?
|
| Rats | 5 | 2023 | 24259 | 0.070 |
Why?
|
| Cadaver | 2 | 2020 | 1330 | 0.070 |
Why?
|
| Blotting, Western | 4 | 2015 | 5180 | 0.070 |
Why?
|
| Adenoviridae | 2 | 2008 | 1095 | 0.070 |
Why?
|
| Logistic Models | 6 | 2017 | 13400 | 0.070 |
Why?
|
| Models, Theoretical | 1 | 2018 | 3605 | 0.070 |
Why?
|
| Neurology | 1 | 2014 | 762 | 0.070 |
Why?
|
| Safety | 1 | 2010 | 1185 | 0.070 |
Why?
|
| Intraoperative Care | 1 | 2009 | 766 | 0.070 |
Why?
|
| Area Under Curve | 2 | 2021 | 1653 | 0.070 |
Why?
|
| Obesity, Morbid | 1 | 2016 | 1191 | 0.070 |
Why?
|
| Chromosome Deletion | 5 | 1996 | 1401 | 0.070 |
Why?
|
| Databases, Bibliographic | 1 | 2005 | 129 | 0.070 |
Why?
|
| Hypothermia, Induced | 2 | 2004 | 746 | 0.060 |
Why?
|
| Brachytherapy | 1 | 2013 | 1247 | 0.060 |
Why?
|
| Genome, Human | 1 | 2018 | 4424 | 0.060 |
Why?
|
| Cerebral Cortex | 2 | 2019 | 5717 | 0.060 |
Why?
|
| Olfactory Receptor Neurons | 1 | 2005 | 92 | 0.060 |
Why?
|
| Infant | 3 | 2019 | 34923 | 0.060 |
Why?
|
| Pulmonary Edema | 1 | 2008 | 415 | 0.060 |
Why?
|
| Patient Care Team | 4 | 2014 | 2527 | 0.060 |
Why?
|
| Models, Biological | 2 | 2019 | 9598 | 0.060 |
Why?
|
| Placebo Effect | 1 | 2008 | 503 | 0.060 |
Why?
|
| Herpesvirus 1, Human | 1 | 2010 | 743 | 0.060 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2014 | 2944 | 0.060 |
Why?
|
| Infant, Newborn | 2 | 2015 | 25470 | 0.060 |
Why?
|
| Apoptosis | 2 | 2013 | 9708 | 0.060 |
Why?
|
| Cost of Illness | 1 | 2014 | 1849 | 0.060 |
Why?
|
| Carotid Artery Thrombosis | 1 | 2004 | 53 | 0.060 |
Why?
|
| Nicardipine | 1 | 2004 | 59 | 0.060 |
Why?
|
| Neoplasm Transplantation | 1 | 2008 | 2083 | 0.060 |
Why?
|
| Macaca mulatta | 1 | 2010 | 2380 | 0.060 |
Why?
|
| p120 GTPase Activating Protein | 1 | 2023 | 39 | 0.060 |
Why?
|
| Electrodes, Implanted | 2 | 2019 | 821 | 0.060 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2002 | 1659 | 0.060 |
Why?
|
| Glossopharyngeal Nerve Diseases | 1 | 2003 | 11 | 0.060 |
Why?
|
| Hernia | 1 | 2004 | 71 | 0.060 |
Why?
|
| Smell | 1 | 2005 | 243 | 0.060 |
Why?
|
| Diagnostic Imaging | 2 | 2014 | 3495 | 0.060 |
Why?
|
| Cell Cycle Proteins | 1 | 2015 | 3432 | 0.060 |
Why?
|
| Hemifacial Spasm | 1 | 2003 | 22 | 0.060 |
Why?
|
| Insurance, Health | 1 | 2016 | 2491 | 0.060 |
Why?
|
| Oxidopamine | 1 | 2023 | 169 | 0.060 |
Why?
|
| Disease-Free Survival | 3 | 2021 | 6870 | 0.060 |
Why?
|
| Disability Evaluation | 3 | 2000 | 1824 | 0.060 |
Why?
|
| Predictive Value of Tests | 5 | 2021 | 15035 | 0.060 |
Why?
|
| Severity of Illness Index | 2 | 2016 | 15510 | 0.060 |
Why?
|
| Internship and Residency | 1 | 2023 | 5761 | 0.060 |
Why?
|
| Activin Receptors, Type II | 1 | 2023 | 127 | 0.060 |
Why?
|
| Anticonvulsants | 1 | 2013 | 1907 | 0.060 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2019 | 2503 | 0.060 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2004 | 338 | 0.060 |
Why?
|
| Luminescent Proteins | 1 | 2006 | 853 | 0.050 |
Why?
|
| Chromatography, Gel | 1 | 2023 | 670 | 0.050 |
Why?
|
| Child, Preschool | 3 | 2015 | 40801 | 0.050 |
Why?
|
| Sex Factors | 1 | 2016 | 10397 | 0.050 |
Why?
|
| Foreign Medical Graduates | 1 | 2023 | 79 | 0.050 |
Why?
|
| Paresis | 1 | 2004 | 179 | 0.050 |
Why?
|
| Speech Disorders | 1 | 2004 | 188 | 0.050 |
Why?
|
| Cerebral Aqueduct | 1 | 2002 | 38 | 0.050 |
Why?
|
| Tomography, Spiral Computed | 1 | 2004 | 279 | 0.050 |
Why?
|
| Fluorouracil | 2 | 2018 | 1609 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2008 | 2614 | 0.050 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2012 | 2299 | 0.050 |
Why?
|
| Brain Infarction | 1 | 2004 | 295 | 0.050 |
Why?
|
| Intracranial Embolism | 1 | 2004 | 202 | 0.050 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2017 | 3101 | 0.050 |
Why?
|
| Quality of Life | 2 | 2020 | 12640 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2009 | 1821 | 0.050 |
Why?
|
| Antibodies, Immobilized | 1 | 2021 | 26 | 0.050 |
Why?
|
| Lumbar Vertebrae | 1 | 2011 | 1843 | 0.050 |
Why?
|
| Genes, p53 | 2 | 1996 | 752 | 0.050 |
Why?
|
| Cancer Vaccines | 1 | 2009 | 1022 | 0.050 |
Why?
|
| Colorectal Neoplasms | 1 | 2021 | 6720 | 0.050 |
Why?
|
| Mesencephalon | 1 | 2023 | 330 | 0.050 |
Why?
|
| Confidence Intervals | 3 | 2016 | 2973 | 0.050 |
Why?
|
| Epigenesis, Genetic | 1 | 2014 | 3629 | 0.050 |
Why?
|
| Avian leukosis virus | 1 | 2000 | 25 | 0.050 |
Why?
|
| Critical Care | 1 | 2014 | 2624 | 0.050 |
Why?
|
| ROC Curve | 2 | 2021 | 3524 | 0.050 |
Why?
|
| Endothelial Growth Factors | 2 | 2002 | 695 | 0.050 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2006 | 1212 | 0.050 |
Why?
|
| Biopsy | 3 | 2017 | 6722 | 0.050 |
Why?
|
| Orthopedic Procedures | 1 | 2011 | 1286 | 0.050 |
Why?
|
| Calcium Channel Blockers | 1 | 2004 | 686 | 0.050 |
Why?
|
| Blood Volume | 1 | 2002 | 565 | 0.050 |
Why?
|
| Incidence | 3 | 2016 | 20912 | 0.050 |
Why?
|
| Sneezing | 1 | 2020 | 17 | 0.050 |
Why?
|
| Kidney Neoplasms | 1 | 2017 | 4190 | 0.050 |
Why?
|
| Sequence Analysis, RNA | 2 | 2022 | 1998 | 0.050 |
Why?
|
| Alleles | 4 | 1993 | 6939 | 0.050 |
Why?
|
| Skull | 1 | 2005 | 809 | 0.050 |
Why?
|
| Prevalence | 5 | 2016 | 15152 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2015 | 3922 | 0.050 |
Why?
|
| Single-Cell Analysis | 2 | 2022 | 2157 | 0.050 |
Why?
|
| Remission, Spontaneous | 1 | 2001 | 377 | 0.050 |
Why?
|
| Lymphokines | 2 | 2002 | 950 | 0.050 |
Why?
|
| Rats, Nude | 1 | 2020 | 106 | 0.050 |
Why?
|
| GTPase-Activating Proteins | 1 | 2023 | 496 | 0.050 |
Why?
|
| Double-Blind Method | 2 | 2018 | 11985 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2015 | 5148 | 0.050 |
Why?
|
| Analysis of Variance | 1 | 2009 | 6364 | 0.050 |
Why?
|
| Fever | 2 | 2007 | 1607 | 0.050 |
Why?
|
| CpG Islands | 2 | 2014 | 1163 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2015 | 3730 | 0.040 |
Why?
|
| Transplantation, Heterologous | 1 | 2008 | 2381 | 0.040 |
Why?
|
| Nerve Degeneration | 1 | 2004 | 759 | 0.040 |
Why?
|
| Intracranial Thrombosis | 1 | 2001 | 112 | 0.040 |
Why?
|
| Data Interpretation, Statistical | 2 | 2009 | 2715 | 0.040 |
Why?
|
| Up-Regulation | 2 | 2019 | 4205 | 0.040 |
Why?
|
| Arteriosclerosis | 1 | 2004 | 1092 | 0.040 |
Why?
|
| Putamen | 1 | 2020 | 291 | 0.040 |
Why?
|
| Gamma Rays | 1 | 2020 | 320 | 0.040 |
Why?
|
| Cerebrovascular Circulation | 2 | 2000 | 2755 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2018 | 1771 | 0.040 |
Why?
|
| Nerve Regeneration | 1 | 2004 | 798 | 0.040 |
Why?
|
| Cells, Cultured | 2 | 2017 | 19223 | 0.040 |
Why?
|
| Sequence Homology | 1 | 2018 | 203 | 0.040 |
Why?
|
| Catheterization | 1 | 2004 | 1466 | 0.040 |
Why?
|
| Electric Conductivity | 1 | 2019 | 411 | 0.040 |
Why?
|
| Antimetabolites | 1 | 2018 | 125 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2004 | 1453 | 0.040 |
Why?
|
| Cell Death | 1 | 2023 | 1691 | 0.040 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2020 | 390 | 0.040 |
Why?
|
| Social Adjustment | 1 | 2000 | 632 | 0.040 |
Why?
|
| Protein Array Analysis | 1 | 2019 | 411 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2005 | 2299 | 0.040 |
Why?
|
| Blood Chemical Analysis | 1 | 2019 | 440 | 0.040 |
Why?
|
| Hematoma | 1 | 2002 | 754 | 0.040 |
Why?
|
| Basal Ganglia | 1 | 2020 | 547 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 5 | 2019 | 21859 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2007 | 1934 | 0.040 |
Why?
|
| Health Resources | 1 | 2023 | 920 | 0.040 |
Why?
|
| Antihypertensive Agents | 1 | 2007 | 2039 | 0.040 |
Why?
|
| Hospitalization | 1 | 2016 | 10208 | 0.040 |
Why?
|
| Neoplasms, Neuroepithelial | 1 | 2017 | 45 | 0.040 |
Why?
|
| Receptors, Virus | 1 | 2000 | 648 | 0.040 |
Why?
|
| Blood Glucose | 2 | 2009 | 6236 | 0.040 |
Why?
|
| Electrophysiological Phenomena | 1 | 2019 | 313 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2018 | 10939 | 0.040 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2018 | 336 | 0.040 |
Why?
|
| Base Sequence | 4 | 2018 | 12807 | 0.040 |
Why?
|
| Cell Proliferation | 3 | 2023 | 10446 | 0.040 |
Why?
|
| Solubility | 1 | 2018 | 1083 | 0.040 |
Why?
|
| Hypoglycemic Agents | 1 | 2009 | 2861 | 0.040 |
Why?
|
| Blood-Brain Barrier | 1 | 2023 | 1013 | 0.040 |
Why?
|
| Prostatectomy | 2 | 1998 | 1858 | 0.040 |
Why?
|
| Surgical Flaps | 1 | 2005 | 1627 | 0.030 |
Why?
|
| Carotid Artery, Common | 1 | 2017 | 183 | 0.030 |
Why?
|
| PubMed | 1 | 2016 | 121 | 0.030 |
Why?
|
| Genes, Tumor Suppressor | 2 | 1991 | 1095 | 0.030 |
Why?
|
| Nervous System Diseases | 2 | 2012 | 1621 | 0.030 |
Why?
|
| Recurrence | 3 | 2021 | 8306 | 0.030 |
Why?
|
| Pandemics | 3 | 2020 | 8274 | 0.030 |
Why?
|
| Dilatation | 1 | 2017 | 286 | 0.030 |
Why?
|
| Particle Size | 1 | 2020 | 1641 | 0.030 |
Why?
|
| DNA, Neoplasm | 2 | 2012 | 1755 | 0.030 |
Why?
|
| Genetic Heterogeneity | 1 | 2019 | 729 | 0.030 |
Why?
|
| Cognition | 1 | 2013 | 6686 | 0.030 |
Why?
|
| Radiography | 3 | 2016 | 6997 | 0.030 |
Why?
|
| Cranial Nerves | 1 | 2016 | 97 | 0.030 |
Why?
|
| Genomics | 1 | 2011 | 5655 | 0.030 |
Why?
|
| Amyloid beta-Peptides | 1 | 2008 | 3570 | 0.030 |
Why?
|
| Persistent Vegetative State | 1 | 1998 | 259 | 0.030 |
Why?
|
| Comet Assay | 1 | 2015 | 72 | 0.030 |
Why?
|
| Neurogenesis | 1 | 2022 | 824 | 0.030 |
Why?
|
| Immunomagnetic Separation | 1 | 2015 | 80 | 0.030 |
Why?
|
| Endothelial Cells | 2 | 2023 | 3433 | 0.030 |
Why?
|
| Archives | 1 | 2014 | 16 | 0.030 |
Why?
|
| Sphenoid Bone | 1 | 2016 | 172 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2020 | 2119 | 0.030 |
Why?
|
| Cavernous Sinus | 1 | 2016 | 125 | 0.030 |
Why?
|
| DNA Methylation | 3 | 2014 | 4268 | 0.030 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2002 | 1822 | 0.030 |
Why?
|
| Obesity | 2 | 2007 | 12641 | 0.030 |
Why?
|
| Lung Neoplasms | 2 | 2016 | 12983 | 0.030 |
Why?
|
| Cholecystectomy | 1 | 2016 | 387 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2010 | 3138 | 0.030 |
Why?
|
| Prodrugs | 1 | 2016 | 268 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2023 | 2552 | 0.030 |
Why?
|
| Insulin | 1 | 2009 | 6568 | 0.030 |
Why?
|
| Endpoint Determination | 1 | 2017 | 598 | 0.030 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2000 | 1358 | 0.030 |
Why?
|
| Spin Labels | 1 | 2015 | 332 | 0.030 |
Why?
|
| RNA, Ribosomal, 18S | 1 | 2013 | 62 | 0.030 |
Why?
|
| RNA Stability | 1 | 2016 | 322 | 0.030 |
Why?
|
| Health Literacy | 1 | 2019 | 413 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 2019 | 1276 | 0.030 |
Why?
|
| Electric Stimulation | 1 | 2019 | 1769 | 0.030 |
Why?
|
| Injections, Spinal | 1 | 2014 | 303 | 0.030 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2018 | 2551 | 0.030 |
Why?
|
| Stroke | 1 | 2016 | 9898 | 0.030 |
Why?
|
| Cell Differentiation | 3 | 2020 | 11471 | 0.030 |
Why?
|
| Thyroidectomy | 1 | 2019 | 876 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 1990 | 6319 | 0.030 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 2 | 2005 | 302 | 0.030 |
Why?
|
| Parturition | 1 | 2016 | 431 | 0.030 |
Why?
|
| Odds Ratio | 4 | 2010 | 9846 | 0.030 |
Why?
|
| Boston | 1 | 2006 | 9314 | 0.030 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2022 | 1847 | 0.030 |
Why?
|
| Neovascularization, Physiologic | 1 | 2000 | 1352 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2020 | 1677 | 0.030 |
Why?
|
| Consensus | 1 | 2021 | 2912 | 0.030 |
Why?
|
| Nerve Net | 1 | 2004 | 2175 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2015 | 804 | 0.030 |
Why?
|
| Positron-Emission Tomography | 2 | 2020 | 6247 | 0.030 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2016 | 873 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2000 | 3769 | 0.030 |
Why?
|
| Cross-Sectional Studies | 3 | 2023 | 24711 | 0.030 |
Why?
|
| Echo-Planar Imaging | 1 | 2016 | 658 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 1993 | 463 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 2020 | 4768 | 0.030 |
Why?
|
| Polymers | 1 | 2019 | 1611 | 0.030 |
Why?
|
| Introns | 1 | 2014 | 992 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2014 | 891 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2020 | 1833 | 0.030 |
Why?
|
| Brain Ischemia | 1 | 2005 | 3245 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2016 | 1251 | 0.020 |
Why?
|
| Cryopreservation | 1 | 2016 | 650 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2018 | 2870 | 0.020 |
Why?
|
| World Health Organization | 1 | 2017 | 1321 | 0.020 |
Why?
|
| Reproducibility of Results | 2 | 2006 | 19787 | 0.020 |
Why?
|
| Penile Erection | 1 | 1991 | 97 | 0.020 |
Why?
|
| Subcellular Fractions | 1 | 2012 | 547 | 0.020 |
Why?
|
| Causality | 2 | 2005 | 1262 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2023 | 2950 | 0.020 |
Why?
|
| Magnetite Nanoparticles | 1 | 2012 | 322 | 0.020 |
Why?
|
| Liposomes | 1 | 2014 | 759 | 0.020 |
Why?
|
| Helper Viruses | 1 | 2010 | 58 | 0.020 |
Why?
|
| Hysterectomy | 1 | 2016 | 926 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2016 | 2296 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2018 | 3909 | 0.020 |
Why?
|
| Central Nervous System Vascular Malformations | 1 | 2012 | 144 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2019 | 2498 | 0.020 |
Why?
|
| Interleukin-13 | 1 | 2012 | 388 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2020 | 23292 | 0.020 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2015 | 1105 | 0.020 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 2011 | 186 | 0.020 |
Why?
|
| Headache | 1 | 1998 | 1199 | 0.020 |
Why?
|
| Molecular Sequence Data | 5 | 2001 | 18124 | 0.020 |
Why?
|
| Cell Line | 3 | 2017 | 15982 | 0.020 |
Why?
|
| Blotting, Southern | 1 | 1990 | 803 | 0.020 |
Why?
|
| Penis | 1 | 1991 | 207 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2023 | 3441 | 0.020 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2005 | 3233 | 0.020 |
Why?
|
| Case-Control Studies | 3 | 2019 | 21691 | 0.020 |
Why?
|
| Histones | 1 | 2020 | 2592 | 0.020 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1990 | 769 | 0.020 |
Why?
|
| DNA Probes | 1 | 1990 | 561 | 0.020 |
Why?
|
| Forecasting | 1 | 1999 | 2952 | 0.020 |
Why?
|
| Cell-Free System | 1 | 2009 | 346 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2018 | 3193 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factors | 2 | 2002 | 773 | 0.020 |
Why?
|
| Membrane Proteins | 2 | 2023 | 7861 | 0.020 |
Why?
|
| Deep Brain Stimulation | 1 | 2017 | 746 | 0.020 |
Why?
|
| Thoracic Vertebrae | 1 | 2014 | 607 | 0.020 |
Why?
|
| Neurologic Examination | 2 | 2003 | 932 | 0.020 |
Why?
|
| Vero Cells | 1 | 2010 | 484 | 0.020 |
Why?
|
| Antibody Affinity | 1 | 2009 | 254 | 0.020 |
Why?
|
| Equipment Design | 1 | 2017 | 3576 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2016 | 2199 | 0.020 |
Why?
|
| Leg | 1 | 2014 | 1106 | 0.020 |
Why?
|
| Translocation, Genetic | 1 | 2014 | 1416 | 0.020 |
Why?
|
| Culture Media, Conditioned | 1 | 2009 | 532 | 0.020 |
Why?
|
| Drug Therapy, Combination | 2 | 2013 | 6478 | 0.020 |
Why?
|
| Lymphoma | 1 | 2017 | 1871 | 0.020 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2002 | 664 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2003 | 5108 | 0.020 |
Why?
|
| Cadherins | 1 | 1992 | 901 | 0.020 |
Why?
|
| Occupations | 1 | 1990 | 517 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 2008 | 423 | 0.020 |
Why?
|
| Protein Multimerization | 1 | 2012 | 969 | 0.020 |
Why?
|
| Stem Cells | 1 | 2020 | 3571 | 0.020 |
Why?
|
| Erectile Dysfunction | 1 | 1991 | 458 | 0.020 |
Why?
|
| Coronary Artery Bypass | 1 | 2016 | 2272 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2018 | 5521 | 0.020 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2008 | 283 | 0.020 |
Why?
|
| Surface Properties | 1 | 2009 | 1181 | 0.020 |
Why?
|
| Epilepsy | 1 | 2002 | 3289 | 0.020 |
Why?
|
| Aging | 1 | 2005 | 8607 | 0.020 |
Why?
|
| Cause of Death | 1 | 1997 | 3564 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2014 | 1501 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2002 | 8553 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2013 | 1516 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2016 | 3419 | 0.020 |
Why?
|
| Receptors, Androgen | 1 | 1992 | 1049 | 0.020 |
Why?
|
| Oncogenes | 1 | 2012 | 1262 | 0.020 |
Why?
|
| Chromosome Mapping | 2 | 1993 | 4744 | 0.020 |
Why?
|
| Hormones | 1 | 1990 | 880 | 0.020 |
Why?
|
| Prostatic Hyperplasia | 1 | 1990 | 522 | 0.020 |
Why?
|
| Pedigree | 1 | 1993 | 4641 | 0.020 |
Why?
|
| Heart Ventricles | 1 | 2018 | 3797 | 0.020 |
Why?
|
| Endotoxins | 1 | 2008 | 524 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2018 | 3328 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2014 | 4174 | 0.020 |
Why?
|
| Neurons | 1 | 2004 | 9340 | 0.020 |
Why?
|
| Contrast Media | 1 | 2018 | 5287 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2014 | 2693 | 0.020 |
Why?
|
| Shivering | 1 | 2004 | 12 | 0.020 |
Why?
|
| Coronary Artery Disease | 1 | 2004 | 6410 | 0.010 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2004 | 231 | 0.010 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2017 | 4025 | 0.010 |
Why?
|
| Electroencephalography | 1 | 2019 | 6133 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2016 | 5462 | 0.010 |
Why?
|
| Environment | 1 | 1990 | 1110 | 0.010 |
Why?
|
| Health Facility Size | 1 | 2003 | 62 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 7274 | 0.010 |
Why?
|
| Medical Oncology | 1 | 2014 | 2216 | 0.010 |
Why?
|
| Plasma Substitutes | 1 | 2002 | 56 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2014 | 8414 | 0.010 |
Why?
|
| Immunotherapy | 1 | 2018 | 4389 | 0.010 |
Why?
|
| Cerebral Arteries | 1 | 2005 | 492 | 0.010 |
Why?
|
| Hospital Bed Capacity | 1 | 2003 | 214 | 0.010 |
Why?
|
| Colloids | 1 | 2002 | 136 | 0.010 |
Why?
|
| Isotonic Solutions | 1 | 2002 | 119 | 0.010 |
Why?
|
| Vasoconstriction | 1 | 2005 | 601 | 0.010 |
Why?
|
| Proteins | 1 | 2017 | 6074 | 0.010 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2016 | 3029 | 0.010 |
Why?
|
| Models, Genetic | 1 | 1992 | 3495 | 0.010 |
Why?
|
| Phenylephrine | 1 | 2002 | 302 | 0.010 |
Why?
|
| Solutions | 1 | 2002 | 426 | 0.010 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2005 | 792 | 0.010 |
Why?
|
| Point-of-Care Systems | 1 | 2009 | 1175 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 2002 | 897 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 2002 | 1103 | 0.010 |
Why?
|
| Reference Values | 1 | 2008 | 4981 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2010 | 3744 | 0.010 |
Why?
|
| Avian Proteins | 1 | 2000 | 80 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 2013 | 6963 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 12945 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 2008 | 2208 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2002 | 3504 | 0.010 |
Why?
|
| Norepinephrine | 1 | 2002 | 911 | 0.010 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2000 | 294 | 0.010 |
Why?
|
| Body Mass Index | 2 | 2007 | 12655 | 0.010 |
Why?
|
| Amino Acid Sequence | 3 | 2001 | 13815 | 0.010 |
Why?
|
| Cardiotonic Agents | 1 | 2002 | 535 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2018 | 15500 | 0.010 |
Why?
|
| Vasoconstrictor Agents | 1 | 2002 | 642 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2007 | 4935 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 2001 | 1676 | 0.010 |
Why?
|
| Breast Neoplasms | 2 | 2017 | 20672 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2001 | 551 | 0.010 |
Why?
|
| Morbidity | 1 | 2003 | 1763 | 0.010 |
Why?
|
| Venous Thrombosis | 1 | 2007 | 1232 | 0.010 |
Why?
|
| Surgical Wound Infection | 1 | 2007 | 1530 | 0.010 |
Why?
|
| Phenotype | 1 | 2014 | 16300 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2003 | 2372 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1996 | 335 | 0.010 |
Why?
|
| Prostate-Specific Antigen | 2 | 1998 | 2440 | 0.010 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2003 | 1440 | 0.010 |
Why?
|
| Capillary Permeability | 1 | 2000 | 799 | 0.010 |
Why?
|
| HeLa Cells | 1 | 2002 | 3118 | 0.010 |
Why?
|
| Patient Admission | 1 | 2003 | 1383 | 0.010 |
Why?
|
| Mannitol | 1 | 1996 | 181 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 1996 | 438 | 0.010 |
Why?
|
| Pulmonary Embolism | 1 | 2007 | 2365 | 0.010 |
Why?
|
| Vision Disorders | 1 | 2001 | 1058 | 0.010 |
Why?
|
| Cell Division | 1 | 2001 | 4575 | 0.010 |
Why?
|
| Heart Failure | 1 | 2016 | 10793 | 0.010 |
Why?
|
| Hypogastric Plexus | 1 | 1991 | 10 | 0.010 |
Why?
|
| Diet | 1 | 1990 | 7875 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1992 | 708 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2000 | 6391 | 0.010 |
Why?
|
| Chromosome Disorders | 1 | 1992 | 516 | 0.010 |
Why?
|
| Homozygote | 1 | 1993 | 1788 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2002 | 4424 | 0.010 |
Why?
|
| Chromosome Aberrations | 1 | 1992 | 1811 | 0.000 |
Why?
|
| Physicians | 1 | 2003 | 4538 | 0.000 |
Why?
|
| Demography | 1 | 1990 | 1650 | 0.000 |
Why?
|
| Prostate | 1 | 1992 | 1742 | 0.000 |
Why?
|
| Binding Sites | 1 | 1992 | 6116 | 0.000 |
Why?
|
| Interviews as Topic | 1 | 1990 | 2533 | 0.000 |
Why?
|
| Regression Analysis | 1 | 1990 | 6451 | 0.000 |
Why?
|